Le Lézard
Classified in: Health, Science and technology
Subjects: Contract/Agreement, Product/Service

IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud


IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce (NYSE:CRM), the #1 AI CRM, today announced an expanded global strategic partnership to accelerate the development of Salesforce's Life Sciences Cloud, a next-generation customer engagement platform for the global life sciences industry.

Building on the IQVIA Orchestrated Customer Engagement (OCE) platform, launched in 2017, the partnership will apply innovations from IQVIA OCE with Salesforce's Life Sciences Cloud to provide customers with a new single, end-to-end engagement platform. Salesforce's leading CRM software, powered by IQVIA data, domain expertise and advanced analytics, is expected to transform healthcare professional (HCP) and patient engagement.

As part of the expanded partnership, IQVIA will license the OCE CRM related software to Salesforce, and the parties will collaborate to accelerate development of Life Sciences Cloud for customer engagement, expected to be available in 2025*. IQVIA will continue to market the OCE CRM product and will support its nearly 400 global OCE customers in 130+ countries through 2029. IQVIA will work with Salesforce to jointly market the new offering. The two companies will bring together talent, technology and expertise to ensure a coordinated transition from IQVIA's OCE to Salesforce's next generation life sciences solution.

"Our expanded relationship with Salesforce will bring the best of our combined capabilities in data, AI and technology to life sciences customers. In collaboration with various strategic partners across multiple healthcare verticals, IQVIA will continue to develop innovative technology solutions to help accelerate decision making across discovery, clinical development, medical affairs, real world evidence generation, patient safety, regulatory compliance, patient engagement and commercial operations," said Bernd Haas, SVP and Head of Digital Products and Solutions at IQVIA.

"Our collaboration with IQVIA marks a pivotal moment for Salesforce Life Sciences Cloud innovation. It will transform the future of HCP engagement, bringing together our combined capabilities in CRM, AI, data, and the thought leadership of IQVIA, all on the trusted Einstein 1 Platform," said Frank Defesche, SVP and General Manager, Life Sciences at Salesforce. "This collaboration will provide life science organizations with a single, intelligent end-to-end engagement platform to transform the customer experience to be orchestrated and personalized."

*While Life Sciences Cloud launches June 2024, Sales automation functions for pharma/biotech customers are currently not offered for sale by Salesforce and will not be available for sale by Salesforce until after September 1, 2025. Commercial functions for medical technology customers are generally available today.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources, extensive domain expertise and network of partners. IQVIA Connected Intelligencetm delivers actionable insights and powerful solutions with speed and agility ? enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

About Salesforce

Salesforce is the #1 AI CRM, empowering companies to connect with their customers in a whole new way through the power of CRM + AI + Data + Trust on one unified platform: Einstein 1. For more information visit: www.salesforce.com (NYSE: CRM).


These press releases may also interest you

at 08:05
Ventus Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVEtm, to develop differentiated small molecule therapeutics, today announced that its...

at 08:05
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2024 first quarter financial results on Monday, May 13, 2024,...

at 08:05
Viridian Therapeutics, Inc. (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent...

at 08:05
Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to...

at 08:05
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...

at 08:00
Sampled1 today announced that it has been named one of the first Olink® Certified Service Providers Olink's state-of-the-art proteomics technology enables understanding of complex biological pathways and disease markers. Proteomics technology is an...



News published on and distributed by: